The two known estrogen receptors, ER␣ and ER␤, mediate the effects of estrogen in all target tissues, including blood vessels. We have shown previously that estrogen inhibits vascular injury response to the same extent in female wild-type (WT), ER␣ knockout (ER␣KO CH ), and ER␤ knockout (ER␤KO CH ) mice. We generated mice harboring disruptions of both ER␣ and ER␤ genes (ER␣,␤KO CH ) by breeding and studied the effect of 17␤-estradiol (E2) on vascular injury responses in ovariectomized female ER␣,␤KO CH mice and WT littermates. E2 inhibited increases in vascular medial area following injury in the WT mice but not in the ER␣,␤KO CH mice, demonstrating for the first time that the two known estrogen receptors are necessary and sufficient to mediate estrogen inhibition of a component of the vascular injury response. Surprisingly, as in WT littermates, E2 still significantly increased uterine weight and inhibited vascular smooth muscle cell (VSMC) proliferation following injury in the ER␣,␤KO CH mice. These data support that the role of estrogen receptors differs for specific components of the vascular injury response in the ER␣,␤KO CH mice. The results leave unresolved whether E2 inhibition of VSMC proliferation in ER␣,␤KO CH mice is caused by a receptor-independent mechanism, an unidentified receptor responsive to estrogen, or residual activity of the ER␣ splice variant reported previously in the parental ER␣KO CH mice. These possibilities may be resolved by studies of mice in which ER␣ has been fully disrupted (ER␣KO St ), which are in progress. (Circ Res. 2001;89:534-539.) Key Words: animal models Ⅲ vascular injury Ⅲ 17␤-estradiol Ⅲ hormone action T he cardiovascular effects of estrogen are diverse. Estrogen
has both systemic effects on circulating factors (eg, cholesterol, cytokines, coagulation/fibrinolytic factors) and direct effects on the blood vessel wall (eg, regulation of vasomotor tone, vascular cell proliferation; reviewed in Mendelsohn and Karas, 1 Farhat et al, 2 and Mendelsohn 3 ) Some of the effects of estrogen occur rapidly, whereas others require prolonged estrogen exposure. At physiologically relevant concentrations of estrogen, both the rapid and the longer-term cardiovascular effects of estrogens are mediated by estrogen receptors. [3] [4] [5] [6] To date, two estrogen receptors (ERs) have been described, ER␣ and ER␤ (reviewed in Gustafsson [1997] , 7 Katzenellenbogen and Korach, 8 and Gustafsson [1999] 9 ). Although their physiological relevance in the vasculature is incompletely understood, ER␣ and ER␤ are expressed in endothelial cells and vascular smooth muscle cells (VSMCs), 10, [11] [12] [13] [14] [15] [16] the predominant cells present in vascular tissues.
Using wild-type (WT) and estrogen receptor knockout (KO) mice, we have previously studied the role of ER␣ and ER␤ in mediating the vascular protective effects of estrogen in a mouse carotid artery injury model. 10, 17, 18 Previous studies used mice developed at the University of North Carolina, Chapel Hill, which harbor gene deletions of either ER␣ (ER␣KO CH ) 19 or ER␤ (ER␤KO CH ). 20 These studies show that treatment of ovariectomized female mice with nanomolar concentrations of 17␤-estradiol (E2) inhibits the response to vascular injury to equivalent levels in wild-type, 17 ER␣KO CH , 10 and ER␤KO CH mice. 18, 21 These findings suggest that ER␣ and ER␤ are able to complement one another such that each receptor alone is sufficient to mediate the vascular protective effects of estrogen, or that the vascular protective effects of estrogen are mediated by an ER␣/ER␤-independent pathway. To distinguish between these two hypotheses, we undertook the present study examining the effect of estrogen on the response to vascular injury in ER␣,␤KO CH (double) estrogen receptor knockout mice.
Materials and Methods Animals
A total of over 820 animals were required to ultimately generate the ER␣,␤KO CH mice used in this study. These mice, which have been extensively studied, do not express ER proteins in any tissue. 19, 20, [22] [23] [24] However, ER␣KO CH mice have been shown previously to express mRNA for 2 partial ER␣ transcripts, one of which retains the hormone-and DNA-binding domains of full-length ER␣, and can both bind estradiol and mediate hormone-induced gene expression. 24 This partial ER␣ transcript, detectable only by reverse transcriptasepolymerase chain reaction approaches, may account for the low level of residual specific binding of estradiol in uterine tissue of the ER␣KO CH mice. 24 ER␣,␤KO CH mice were generated by extensive crossbreeding in one of our laboratories (C.O.) as follows: male and female double heterozygous (ER␣ ϩ/Ϫ ␤ ϩ/Ϫ ) mice were created from the parental ER␣KO CH and ER␤KO CH mice. Female offspring with the wild-type ER␣ ϩ/ϩ ␤ ϩ/ϩ genotype and the double receptor knockout ER␣ Ϫ/Ϫ ␤ Ϫ/Ϫ genotype were included in the present study, 19, 20, 25 and the latter are referred to as ER␣,␤KO CH . More than 830 mice were required to generate a sufficient number of ER␣,␤KO CH female mice for the study. All mice were of mixed C57BL/6J/129 backgrounds. Genotyping of tail DNA was performed at 4 weeks of age and again at the end of the vascular injury experiment on tail snips. The ER␣ gene was analyzed with the following primer pairs. Primers AACTCGCCGGCTGCCACTTACCAT and CATCAGCGGGCTAG-GCGACACG for the WT gene correspond to flanking regions in the targeted exon 2. They produce a fragment of 320 bp. Primers TGTG-GCCGGCTGGGTGTG and GGCGCTGGGCTCGTTCTC for the knockout gene correspond to part of the Neo cassette and the flanking exon 2. They produce a 700-bp fragment. Genotyping of the ER␤ gene has been described previously. 26 
Carotid Artery Injury
All procedures and protocols were approved by the New England Medical Center Animal Research Committee. A detailed description of the vascular injury protocol has been published previously. 10, 17, 18 Briefly, 7 days following ovariectomy, 26 wild-type and 23 ER␣,␤KO CH female mice, average age 12 to 13 weeks, were randomized to receive either placebo pellets (ϪE2) or 17␤-estradiolcontaining pellets (ϩE2; 0.1 mg/21-day pellets, Innovative Research) at a dose previously shown to produce physiologically relevant (ie, low nanomolar) concentrations of circulating 17␤estradiol (E2). A week after pellets were implanted, the mice were anesthetized with inhaled isoflurane and subjected to unilateral vascular injury by intraluminal passage of a wire into the left common carotid artery resulting in endothelial denudation. At this time, osmotic minipumps calibrated to release bromodeoxyuridine (BrdU) over the 14 days of the experiment were implanted subcutaneously, as described. 17 The mice were allowed to recover and return to normal activity.
Tissue Harvest
Two weeks following vascular injury, the mice were anesthetized with 2.5% isoflurane and blood was taken for cholesterol and estradiol determinations. Uteri where then extracted and wet weights obtained, followed by harvesting of a small segment of the tail for confirmation of prestudy genotype analysis by reverse transcriptasepolymerase chain reaction. Both carotid arteries were harvested next after perfusion fixation with 10% formalin at 150 mm Hg for 4 minutes. A small segment of small intestine was also harvested for use as a positive control for the BrdU stains (see next section).
Immunohistochemistry and Morphometry
Following embedding in paraffin, parallel sections from all 98 carotid arteries were stained as previously described for hematoxylin/eosin and for elastin. 10, 17, 18, 27 Immunodetection of BrdU-labeled cells was also performed as previously described. 10, 17, 18 A section of small intestine was included on each slide to serve as a positive control for the BrdU stain. One section of each vessel was not exposed to a primary antibody, serving as a negative control. VSMCs were identified by immunostaining for smooth muscle specific actin, performed on a Vantana automated slide staining machine using clone 1A4 from Sigma as the primary antibody. BrdU-stained VSMCs and unstained VSMC nuclei were counted by two independent observers. A VSMC proliferation index also was calculated by dividing the number of BrdU-labeled VSMCs by the total number of unstained VSMCs for each section. Medial area was determined on serial elastin-stained sections using the ImagePro Plus software. All observations were made by observers blinded to both the genotype and the treatment group of the specimen. Only one vessel developed an occlusive thrombosis, and this mouse from the WTϪE2 group was excluded from analysis.
Additional Assays
Circulating concentrations of E2 were measured by radioimmunoassay using a commercially available kit (Ultra-Sensitive Estradiol RIA, Diagnostic System Laboratories Inc), according to the manufacturer's instructions. Pooled samples of serum (200 L) from each of the treatment groups were each assayed in triplicate, and the mean value is reported as representative of the group. Control experiments confirmed the linearity of the assay between the range of 0.018 and 2.78 nmol/L. Circulating concentrations of total and HDL cholesterol, and triglycerides were determined as previously described. 17 At the time of euthanasia, the correct genotype of each mouse was confirmed by a second independent set of PCR studies using tail-snip DNA as described above.
Statistical Analysis
For all analyses, differences between the 4 treatment groups were first examined with a one-way ANOVA after the normality of the data were tested. Post hoc comparisons were made with the Student-Newman-Keuls test. Two group comparisons were made with the Student's t test. All statistics were performed using SigmaStat software. A value of PՅ0.05 was considered significant.
Results
As in our previous studies, implantation of E2-containing pellets in the ovariectomized female mice restored circulating levels of E2 to physiological levels in both the WT and ER␣,␤KO CH mice (0.43Ϯ0.03 nmol/L [115Ϯ9 pg/mL] and 0.55Ϯ0.03 nmol/L [148Ϯ7 pg/mL], respectively; Table) . There were no significant differences in body weight, blood pressure, or heart rate at baseline or at the time of injury between any of the groups (Table) . Cholesterol levels also were similar between the WT and ER␣,␤KO CH animals, and not significantly changed by estrogen treatment (Table) . In the WT animals, E2 treatment resulted in the expected approximately 10-fold increase in uterine weight compared with the ϪE2 group (Figure 1 ; PϽ0.001 WTϩE2 versus WTϪE2). The uterine weights were lower in the placebotreated ER␣,␤KO CH mice than in the placebo-treated WT mice (PϽ0.01 ER␣,␤KO CH ϪE2 versus WTϪE2). Surprisingly, E2 replacement to physiological levels also significantly increased uterine weight in the ER␣,␤KO CH mice (5.8-fold; Figure 1 ; PϽ0.01 ER␣,␤KO CH ϩE2 versus ER␣,␤KO CH ϪE2), although to a lesser extent than in the WT mice. Uterine weight increased in every animal assigned to receive E2-containing pellets, confirming proper placement and function of the pellets.
The 2 primary endpoints for the mouse carotid artery injury model are well established 10, 17, 18 and include (1) change in medial area and (2) extent of VSMC proliferation, both assessed 14 days after unilateral endothelial denudation injury. The medial-area endpoint reflects the combined effects of alterations in extracellular matrix constituents and cellular volume, whereas the VSMC proliferation endpoint specifically indicates the degree of mitogenesis that occurs in these cells in response to the vascular injury.
Response to Vascular Injury: Medial Area
Medial areas were determined by computerized morphometric analysis of elastin-stained sections of each carotid artery. A summary of the medial area results is presented in Figure 2 . The medial areas of the uninjured carotid arteries were similar in the WT (nϭ26) and ER␣,␤KO CH (nϭ23) mice (15.5Ϯ0.3ϫ 10 Ϫ3 mm 2 versus 15.3Ϯ0.5ϫ10 Ϫ3 mm 2 , respectively; PϭNS). In the placebo-treated WT mice, injury induced an increase in the medial area to 21.3Ϯ1.6ϫ10 Ϫ3 mm 2 (PϽ0.01 WTϪE2 versus uninjured). Estrogen replacement in the WT mice significantly inhibited the injury-induced increase in medial area, resulting in a medial area of 16.0Ϯ1.4ϫ10 Ϫ3 mm 2 (Pϭ0.03 WTϩE2 versus WTϪE2). The medial area of the injured carotid in the WTϩE2 animals was indistinguishable from that of the uninjured contralateral vessel (Pϭ0.7 WTϩE2 versus uninjured).
In the placebo-treated ER␣,␤KO CH mice, injury induced a significant increase in medial area (20.3Ϯ1.1ϫ10 Ϫ3 mm 2 ; PϽ0.01 ER␣,␤KO CH ϪE2 versus uninjured), similar to the degree of injury response in the placebo-treated WT mice (Pϭ0.6 ER␣,␤KO CH ϪE2 versus WTϪE2). In contrast to the findings in the WT mice, in the ER␣,␤KO CH mice E2 treatment did not significantly inhibit the injury-induced increase in medial area (19.0Ϯ0.7ϫ10 Ϫ3 mm 2 in the ER␣,␤KO CH ϩE2, Pϭ0.5 versus ER␣,␤KO CH ϪE2). Thus, the injury-induced increase in medial area was similar in the placebo-treated WT and ER␣,␤KO CH mice, but E2 replacement no longer inhibited the increase in medial area following injury in the ER␣,␤KO CH mice. In contrast to any of our previous studies using this model, in over 300 animals (References 10, 17, 18, and unpublished results, 2000 -2001), these results in the ER␣,␤KO CH mice represent the first instance that E2 has failed to protect against an endpoint analyzed to quantify the vascular response to carotid injury.
Response to Vascular Injury: VSMC Proliferation
VSMC proliferation was assessed by immunohistochemical detection of BrdU-labeled VSMCs in sections from each carotid artery. A summary of these results is presented in Figure 3 . There were no differences in the morphological appearance or total number of nuclei in the uninjured vessels of the WT and ER␣,␤KO CH mice (95Ϯ15 versus 93Ϯ14 cells/section, respectively; PϭNS). This supports that there are no obvious developmental abnormalities in the formation of the vasculature in the ER␣,␤KO CH mice. As expected, BrdU-labeled VSMCs were only rarely detected in the uninjured vessels of either the WT or the ER␣,␤KO CH mice (mean Ͻ1 labeled cell per vessel for WT and ER␣,␤KO CH groups; PϭNS between groups). As in our previous studies using this injury technique, a small amount of neointima was observed in a minority of injured vessels and there were no significant differences in neointimal formation in the WT compared with the ER␣,␤KO CH mice (data not shown). In the placebo-treated WT mice, injury increased the VSMC proliferation index from Ͻ0.1 to 1.1Ϯ0.3 (PϽ0.001 WTϪE2 versus uninjured). This increase in VSMC proliferation was significantly attenuated by E2 treatment in the WT mice, resulting in a VSMC proliferation index of 0.5Ϯ0.1 (PϽ0.05 WTϩE2 versus WTϪE2). In the placebo-treated ER␣,␤KO CH mice, injury also induced an increase in the VSMC proliferation index from Ͻ0.1 to 0.8Ϯ0.1 (PϽ0.001 ER␣,␤KO CH ϪE2 versus uninjured). The injury-induced increase in VSMC proliferation in the placebotreated ER␣,␤KO CH mice was similar to that observed in the placebo-treated WT mice (Pϭ0.4 ER␣,␤KO CH ϪE2 versus WTϪE2). As in the WT mice, E2 treatment of the ER␣,␤KO CH mice significantly attenuated the injury-induced increase in the VSMC proliferation index (0.4Ϯ0.1; PϽ0.05 ER␣,␤KO CH ϩE2 versus ER␣,␤KO CH ϪE2; Pϭ0.6 ER␣,␤KO CH ϩE2 versus WTϩE2). Thus, injury induced an increase in VSMC proliferation to similar degrees in the placebo-treated WT and ER␣,␤KO CH mice, and the inhibitory effect of E2 on the injury-induced increase in VSMCs observed in the WT animals was retained in the ER␣,␤KO CH mice. These findings demon-strate maintenance of the protective effect of E2 on VSMC proliferation in the ER␣KO CH mice, in surprising contrast to the loss of the protective effect of E2 on the medial-area endpoint presented above.
Effects of E2 on Wild-Type and ER␣,␤KO CH Mice

Discussion
Recent data demonstrate clearly that estrogen receptors mediate both genomic and nongenomic effects in vascular cells at physiological levels of estrogen. [3] [4] [5] [6] ER␣ was the first and only known estrogen receptor from 1985, when it was initially cloned, 28 until 1996, when ER␤ was discovered. 29 -31 Although ER␣ and ER␤ are the products of distinct genes, they share relatively high degrees of homology in the DNA binding domain (Ϸ95%) and in the ligand binding domain (Ϸ55%). Recent studies have begun to define receptorspecific differences in ligand binding affinity, 29,32-34 receptor interacting proteins, 35, 36 and pharmacologic agonists and and injured (Inj) carotid arteries from wild-type (WT) and ER␣,␤KO CH mice treated with placebo pellets (ϪE2), or 17␤-estradiol-containing pellets (ϩE2) are shown (ϫ400). The medial area of each specific section shown is listed in parentheses. The medial area was determined on the entire section. a, Wild-type, uninjured (15.5ϫ10 Ϫ3 mm 2 ). b, Wild-type, injured, placebo-treated (22.2ϫ10 Ϫ3 mm 2 ). c, Wild-type, injured, E2-treated (15.4ϫ10 Ϫ3 mm 2 ). d, ER␣,␤KO CH , uninjured (14.7ϫ10 Ϫ3 mm 2 ). e, ER␣,␤KO CH , injured, placebo-treated (21.6ϫ10 Ϫ3 mm 2 ). f, ER␣,␤KO CH , injured, E2-treated (18.9ϫ10 Ϫ3 mm 2 ). g, Summary of medial area results for all mice. In panel b, the external elastic lamina is identified by the red arrow, and the internal elastic lamina is identified by the black arrow. In panel g, bars represent the mean value for each group, ϮSEM. *PϽ0.05 vs the inj, ϪE2 group within the same genotype. antagonists. [37] [38] [39] These findings highlight the potential for differences in the physiological effects of these two receptors.
In 1995, we first reported that estrogen inhibits the vascular injury response in normolipemic wild-type mice, 17 as it does in other animal models (reviewed in Mendelsohn and Karas 1 ). A subsequent study showed equivalent inhibition of the vascular injury response in the ER␣KO CH mice created by Lubahn et al 19 compared with their littermate wild-type controls. 10 A more recent study in which ER␣KO CH mice were bred with the hyperlipidemic apolipoprotein E knockout mice demonstrated that in this model estrogen no longer decreased plaque size, but continued to significantly alter plaque complexity, decreasing the number of lesions with fibrous caps, calcifications, and cholesterol clefts. 40 These studies support the existence of ER␣-independent vascular protective effects of E2 or of residual ER␣ activity in the ER␣KO CH mice. 24 The discovery of ER␤, 29 identification of its expression in vascular cells and tissues, 10 and demonstration that vascular injury dramatically enhances vascular cell expression of ER␤ but not ER␣ 13, 16 all raised expectations that ER␤ might mediate the vascular protective effects of estrogen. However, a subsequent carotid artery injury study in the ER␤KO mice demonstrated that E2 continued to inhibit the response to injury equally well in ER␤KO and WT mice. 18 These studies, which used the only available ER knockout mice at that time, 19, 20 suggested that neither ER␣ nor ER␤ by themselves are necessary for the protective effect of estrogen in the vasculature.
In the present study, the effect of E2 on the usual two vascular injury endpoints, medial area and VSMC proliferation, was compared in ER␣,␤KO CH and WT mice. In the wild-type mice, E2 inhibited the injury-induced increase in medial area as it has in each of our previous studies. 10, 17, 18 In contrast, in the ER␣,␤KO CH mice, E2 did not prevent the injury-induced increase in medial area. Loss of the protective effect of estrogen on the medial-area endpoint in the ER␣,␤KO CH mice supports that ER␣ and ER␤ mediate this effect of estrogen. Thus, for the first time, ER␣ and ER␤ are implicated as physiologically relevant mediators of one component of the vascular injury response. Taken together with the results of previous single estrogen receptor knockout experiments, 10, 18 these data support that the ER␣ and ER␤ can functionally complement one another in vivo, such that either receptor alone can mediate the inhibitory effect of E2 on the medial area thickening endpoint (see subsequent caveat).
The E2-mediated inhibition of VSMC proliferation observed in the WT mice in the present study also is consistent with our previous observations in the WT mice. 10, 17, 18 Quite surprisingly, however, estrogen also inhibited VSMC proliferation in the ER␣,␤KO CH mice to a similar extent as in the WT mice. One interpretation of the preserved estrogenic effect on VSMC proliferation in ER␣,␤KO CH mice is the exciting possibility that there are estrogen receptors other than ER␣ and ER␤ that have not yet been identified. However, to date, extensive searching has failed to identify any likely candidates (authors' unpublished results, 1997-2001).
It is important to note that E2-mediated inhibition of VSMC proliferation was not the only estrogenic effect observed in the ER␣,␤KO CH mice. Estrogen exposure also resulted in a significant increase in ER␣,␤KO CH uterine weights (Figure 1 ). This demonstrates that preservation of an effect of estrogen in the ER␣,␤KO CH mice is not confined to, or specific for, the cardiovascular system. The estrogen responsiveness of the uterus in these mice raises an additional consideration. The ER␣,␤KO CH mice used in the present study were produced by breeding ER␣KO CH and ER␤KO CH mice. 19, 20, 22, 23 Uteri of ER␣KO CH mice express mRNA for 2 partial ER␣ transcripts. 24 Although one of these transcripts is nonfunctional, the other transcript, E1, is a splice variant of the wild-type ER␣ in which only a portion of exon 2 is omitted. 24 The protein encoded by this mutant sequence appears to bind estrogen with an affinity similar to that of the wild-type receptor, and to be capable of mediating hormoneinduced gene expression. 24 In this prior study, immunoblot analyses of ER␣KO CH uterus did not detect expression of a protein from the E1 splice variant. 24 However, it remains quite possible that the estrogenic effects observed on VSMC proliferation and uterine weight in the present study are mediated by expression of low levels of this mutant ER␣. If the E1 transcript mediates the effects of estrogen on uterine weight and/or VSMC proliferation in the ER␣,␤KO CH mice (and the parental ER␣KO CH mice 10 ), this would have widespread implications for the published reports that have used ER␣KO CH mice to study various physiological systems (reviewed in Couse and Korach 41 ).
The mechanism by which estrogen continues to inhibit VSMC proliferation and increase uterine weight in the ER␣,␤KO CH mice thus remains unclear. Receptorindependent effects of estradiol could be involved, although there is little physiological evidence in support of this explanation. 1 The presence of an unidentified, novel estrogen receptor could also account for the persistent ability of E2 to inhibit VSMC proliferation, although no ER␥ has been identified despite extensive searching. However, another member of the steroid hormone receptor superfamily 42 (eg, ERR␣, ERR␤, ERR␥, or an orphan receptor) with the ability to respond to estrogen could be involved. Alternatively, a low level of expression of the E1 estrogen receptor splice variant identified by Couse et al 24 in the ER␣KO CH parental strain could mediate residual estrogen responsiveness in ER␣,␤KO CH mice. The explanation for persistent effects of estrogen in this study may be resolved by our ongoing studies of the effect of E2 on the vascular injury response in mice recently created in the Chambon laboratory in Strasbourg, France (ER␣KO St ), 43 in which ER␣ has been fully disrupted. Understanding the mechanism by which estrogen responsiveness is retained in the ER␣,␤KO CH mice has important implications for our understanding of estrogen receptormediated signaling in all target tissues, including the cardiovascular system.
